Over the last 7 days, the United States market has risen by 5.7%, contributing to a remarkable increase of 37% over the past year, with earnings anticipated to grow by 16% annually in the coming years. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
AsiaFIN Holdings |
51.75% |
58.17% |
★★★★★★ |
|
Invivyd |
47.87% |
67.72% |
★★★★★★ |
|
Sarepta Therapeutics |
23.89% |
42.65% |
★★★★★★ |
|
TG Therapeutics |
34.66% |
56.48% |
★★★★★★ |
|
Alkami Technology |
21.89% |
98.60% |
★★★★★★ |
|
Alnylam Pharmaceuticals |
22.45% |
70.66% |
★★★★★★ |
|
Blueprint Medicines |
25.26% |
68.92% |
★★★★★★ |
|
Travere Therapeutics |
31.20% |
72.26% |
★★★★★★ |
|
Seagen |
22.57% |
71.80% |
★★★★★★ |
|
ImmunoGen |
26.00% |
45.85% |
★★★★★★ |
Click here to see the full list of 243 stocks from our US High Growth Tech and AI Stocks screener.
Let’s review some notable picks from our screened stocks.
Simply Wall St Growth Rating: ★★★★★☆
Overview: CleanSpark, Inc. operates as a bitcoin miner in the Americas with a market cap of $3.50 billion.
Operations: The company generates revenue primarily through its Bitcoin Mining Business, which reported $342.21 million. The focus on bitcoin mining highlights a concentrated revenue stream within the digital currency sector.
CleanSpark, showcasing resilience and adaptability, recently resumed operations post-Hurricane Helene with a hashrate rebound to 28.7 EH/s, underscoring its robust recovery mechanisms. Amidst operational updates, the company also expanded its financial flexibility by doubling authorized shares to 600 million, reflecting potential for future growth initiatives or equity-based financing. Financially, CleanSpark is poised for significant growth with revenue expected to surge at an annual rate of 37.2%, outpacing the broader US market’s 8.9%. Moreover, earnings are projected to skyrocket by approximately 83.4% annually over the next three years, indicating strong future profitability despite current unprofitability and recent shareholder dilution.
Simply Wall St Growth Rating: ★★★★★★
Overview: TG Therapeutics, Inc. is a commercial stage biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases globally, with a market cap of $4.13 billion.
Operations: TG Therapeutics focuses on developing and commercializing treatments for B-cell mediated diseases, generating revenue primarily from its biotechnology startup segment, which amounts to $264.79 million.
TG Therapeutics has demonstrated a notable resilience in its financial and operational performance, with revenue growth forecasted at 34.7% annually, significantly outpacing the US market average of 8.9%. This robust expansion is underpinned by promising clinical outcomes from their ULTIMATE I & II Phase 3 trials for BRIUMVI in multiple sclerosis, showing a marked reduction in annualized relapse rates and stable immunoglobulin levels over five years. Despite recent setbacks reflected in Q3 earnings—where net income sharply fell to $3.88 million from $113.93 million year-over-year—the company’s strategic inclusion in indices such as the S&P 1000 underscores its potential within the biotech sector. With R&D efforts yielding continuous treatment benefits and safety profiles, TG Therapeutics is poised to leverage its scientific advancements for future growth, especially as it transitions towards profitability with an expected profit surge of 56.5% annually over the next three years.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Ubiquiti Inc. develops networking technology for service providers, enterprises, and consumers with a market capitalization of approximately $18.92 billion.
Operations: The company generates revenue primarily from its Wireless Communications Equipment segment, which accounted for approximately $2.02 billion.
Ubiquiti’s recent financial performance underscores its resilience in the tech sector, with a notable increase in quarterly sales from $463.08 million to $550.34 million and a jump in net income from $87.75 million to $127.99 million, reflecting a robust growth trajectory. This upward trend is mirrored by an anticipated annual earnings growth of 29% over the next three years, outpacing the US market forecast of 15.5%. Despite being dropped from the FTSE All-World Index, Ubiquiti maintains strong shareholder returns with consistent dividend affirmations, highlighting its commitment to delivering value amidst dynamic market conditions. The company’s strategic focus on innovation is evident from its R&D investments aimed at driving further growth within the competitive tech landscape.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqCM:CLSK NasdaqCM:TGTX and NYSE:UI.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com